The (near) equivalence of cost-effectiveness and cost-benefit analyses. Fact or fallacy?

PharmacoEconomics

Volumn 13, Issue 4, 1998, Pages 389-396

  Donaldson, Cam ^a,b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BUDGET; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; ECONOMIC EVALUATION; HEALTH ECONOMICS; HUMAN; MEDICAL INFORMATION; PHARMACOECONOMICS; PRIORITY JOURNAL;

COST-BENEFIT ANALYSIS; ECONOMICS, PHARMACEUTICAL;

EID: 0031909890     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199813040-00002     Document Type: Article

References (31)

1. Maynard A. Economic evaluation techniques in healthcare. Pharmacoeconomics 1997; 11 (2): 115-8
2. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ 1997; 16: 1-31
3. Meltzer D. Accounting for future costs medical cost-effectiveness analysis. J Health Econ 1997; 16: 33-64
4. Phelps CE, Mushlin AI. On the (near) equivalence of cost-effectiveness and cost-benefit analyses. Int J Technol Assess Health Care 1991; 7: 12-21
5. Mooney GH. Economic evaluation: the Australian road to health service efficiency. In: Health care evaluation - report of the National Health Care Evaluations Workshop, July 1989. Canberra: Public Health Association of Australia, 1989
6. Mishan EJ. Cost-benefit analysis. 4th ed. London: Unwin Hyman, 1988
7. Dreze J, Stern N. The theory of cost-benefit analysis. In: Auerbach AE, Feldstein M, editors. Handbook of public economics. Vol. II. Amsterdam: Elsevier Science Publishers, 1987
8. Johannesson M. The relationship between cost-effectiveness analysis and cost-benefits analysis. Soc Sci Med 1995; 41: 483-9
9. Drummond MF, Stoddart GL. Economic evaluation of health-producing technologies across different countries. Health Policy 1995; 33: 219-31
10. Donaldson C, Shackley P. Economic evaluation. In: Detels R, Holland WW, McEwen J, et al., editors. Oxford textbook of public health. Vol. 2: the methods of public health. 3rd ed. Oxford: Oxford University Press, 1997: 849-71
11. Birch S, Donaldson C. Applications of cost benefit analysis to health care: departures from welfare economic theory. J Health Econ 1987; 6: 211-25
12. Culyer AJ. Economics. Oxford: Blackwell, 1985
13. Gould D. A groundling's notebook. New Scient 1971; 51: 217
14. Gravelle H, Rees R. Microeconomics. London: Longman, 1981
15. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
16. Drummond MF, O'Brien B, Stoddart GL, et al. Methods for the economic evaluation of health care programmes. 2nd ed. Oxford: Oxford University Press, 1997
17. Russell IT, Devlin B, Fell M, et al. Day case surgery for hernias and haemorrhoids: a clinical, social and economic evaluation. Lancet 1977; 1: 844-7
18. Doesell DP. Economic analysis and end stage renal disease: an Australian study. Econ Anal Policy 1978; 8: 21-36
19. Donaldson C, Mapp T, Farrar S, et al. Assessing community values in health care: is the 'willingness to pay' method feasible? Health Care Anal 1997; 5: 7-29
20. Luce BR, Simpson K. Methods of cost-effectiveness analysis: areas of consensus and debate. Clin Ther 1995; 17: 109-25
21. Freund DA, Dittus RS. Principles of pharmacoeconomic analysis of drug therapy. Pharmacoeconomics 1992; 1 (1): 20-9
22. Henry D. Economic analysis as an aid to subsidisation: the development of Australian guidelines for pharmaceuticals. Pharmacoeconomics 1992; 1 (1): 54-67
23. Kristiansen IS, Eggen AE, Thelle DS. Cost effectiveness of incremental programmes for lowering serum cholesterol concentration: is individual intervention worthwhile? BMJ 1991; 302: 1119-22
24. Johannesson M, Jonsson B, Kjekshus J, et al. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997; 336: 332-6
25. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332: 1418-24
26. Birch S, Gafni A. Cost-effectiveness ratios: in a league of their own. Health Policy 1994; 28: 133-41
27. Ortega A, Dranitsaris G, Sturgeon J, et al. Cost-utility analysis of paclitaxel in combination with cisplatin for patients with advanced ovarian cancer. Gynecol Oncol 1997; 66: 454-63
28. McGuire W, Neugut AI, Arikian S, et al. Analysis of the cost effectiveness of paclitaxel as alternative combination therapy for advanced ovarian cancer. J Clin Oncol 1997; 15: 640-5
29. Elit LM, Gafni A, Levine MN. Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective. J Clin Oncol 1997; 15: 632-9
30. Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. Can Med Assoc J 1993; 148: 913-7
31. Birch S, Gafni A. Cost effectiveness/cost utility analyses: do current decision rules take us to where we want to be? J Health Econ 1992; 11: 279-96